/**/ RNS Number : 3367X IQ-AI Limited 04 January 2022 4 January 2022 IQ-AI Ltd (“IQ-AI” or the “Company”) Director/PDMR Shareholding IQ-AI announces that Michael Schmainda, Director of IQAI and CEO of Imaging Biometrics, has been granted an option to subscribe for 5,969,792 ordinary shares of 1p each in the Company (“Ordinary
/**/ RNS Number : 0182W IQ-AI Limited 17 December 2021 17 December 2021 IQ-AI LIMITED (“IQ-AI” or the “Company”) IQ-AI Prepares for Phase I Clinical Trial Launch IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), IQ-AI has been working with the clinical team at the Medical College of Wisconsin (MCW) to qualify a new supplier for
/**/ RNS Number : 4300V IQ-AI Limited 13 December 2021 13 December 2021 IQ-AI Ltd (“IQ-AI” or the “Company”) Director’s Interest IQ-AI has been advised that Trevor Brown, Chief Executive of the Company, no longer has an interest in Free Association Books Limited. Accordingly, Trevor Brown’s interest in the Company is now
/**/ RNS Number : 0487R IQ-AI Limited 02 November 2021 FOR IMMEDIATE RELEASE MD ANDERSON ADOPTS IB CLINIC FOR BRAIN TUMOR ANALYSIS Installation Includes IB Neuro™ and IB DCE™ Software Purchase also Includes IB Clinic – Mac Edition Milwaukee – 2 November 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer and manufacturer
/**/ RNS Number : 6279Q IQ-AI Limited 28 October 2021 28 October 2021 IQ-AI Ltd (“IQ-AI” or the “Company”) IQ-AI LIMITED ISSUES SHAREHOLDER LETTER Company Enjoys Most Successful Year on Record Marked Increase in Revenue and Growing Technology Portfolio Sponsorship of a Phase I Clinical Trial Milwaukee – 28 October 2021: IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), a
/**/ RNS Number : 3746O IQ-AI Limited 07 October 2021 7 October 2021 IQ-AI Ltd (“IQ-AI” or the “Company”) Placing IQ-AI is pleased to announce that it has raised £620,000 through the placing of 12,400,000 new ordinary shares of 0.01p each in the Company (“Ordinary Shares”, the “Placing Shares”) at a price
/**/ RNS Number : 5128M IQ-AI Limited 22 September 2021 22 September 2021 IQ-AI Limited (“IQ-AI” or the “Company”) IQ-AI LIMITED AWARDED EU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING Milwaukee – 22 September 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer and manufacturer of medical image processing platforms that have led to effective
/**/ RNS Number : 0638M IQ-AI Limited 17 September 2021 17 September 2021 IQ-AI Limited (“IQ-AI” or the “Company”) IB Software Chosen for Quantitative Accuracy and Automation IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF) today announced the sale of multiple licenses of Imaging Biometrics (IB) software for the automated generation of quantitative perfusion maps. The
/**/ RNS Number : 3307L IQ-AI Limited 10 September 2021 September 10, 2021 IQ-AI Limited (“IQ-AI” or the “Company”) IQ-AI update on Phase I clinical trial and software sales IQ-AI Limited (LSE: IQAI, OTCQB: IQAIF) announces that the Gallium Maltolate phase I clinical trial will now commence towards the end of Q4
/**/ RNS Number : 4651K IQ-AI Limited 02 September 2021 2 September 2021 IQ-AI Limited (“IQ-AI” or the “Company”) Board Changes IQ-AI Limited (LSE: IQAI; OTCQB: IQAIF) announces that Brett Skelly has been appointed as a non-executive Director of the Company with immediate effect. Brett has been working in the financial